Equities

Gunsynd PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Gunsynd PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.12
  • Today's Change0.003 / 2.13%
  • Shares traded1.01m
  • 1 Year change-5.88%
  • Beta0.7630
Data delayed at least 20 minutes, as of Feb 17 2026 11:17 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Jul 31 2025202520242023
ASSETS
Cash And Short Term Investments0.440.150.16
Total Receivables, Net0.160.200.17
Total Inventory------
Prepaid expenses--0.060.03
Other current assets, total------
Total current assets0.600.410.36
Property, plant & equipment, net0.40----
Goodwill, net------
Intangibles, net------
Long term investments1.161.301.89
Note receivable - long term0.16----
Other long term assets------
Total assets2.311.702.25
LIABILITIES
Accounts payable--0.060.06
Accrued expenses--0.060.04
Notes payable/short-term debt--00
Current portion long-term debt/capital leases------
Other current liabilities, total--0.03--
Total current liabilities0.170.150.10
Total long term debt--00
Total debt--00
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities0.170.150.10
SHAREHOLDERS EQUITY
Common stock3.562.822.68
Additional paid-in capital141413
Retained earnings (accumulated deficit)(15)(15)(14)
Treasury stock - common(0.08)(0.04)(0.03)
Unrealized gain (loss)------
Other equity, total------
Total equity2.141.562.15
Total liabilities & shareholders' equity2.311.702.25
Total common shares outstanding1,487611450
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.